Synonyms: HMS-5552 | HMS5552 | RO-5305552 | RO5305552 | Sinogliatin
dorzagliatin is an approved drug (China (2022))
Compound class:
Synthetic organic
Comment: Dorzagliatin (HMS5552) is an allosteric glucokinase (GCK) activator [3,5], that targets both pancreatic and hepatic GCK, and is a 'full' activator that increases GCK's maximum velocity (Vmax) [7]. GCK activators are being developed as novel drugs for the treatment of type 2 diabetes mellitus (T2DM) [1-2,4].
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
Approved drug? | Yes. China (2022) |
International Nonproprietary Names ![]() |
|
INN number | INN |
10511 | dorzagliatin |
Synonyms ![]() |
HMS-5552 | HMS5552 | RO-5305552 | RO5305552 | Sinogliatin |
Database Links ![]() |
|
ChEMBL Ligand | CHEMBL4297508 |
DrugBank Ligand | DB15123 |
GtoPdb PubChem SID | 472319246 |
PubChem CID | 57920094 |
Search Google for chemical match using the InChIKey | HMUMWSORCUWQJO-QAPCUYQASA-N |
Search Google for chemicals with the same backbone | HMUMWSORCUWQJO |
Search PubMed clinical trials | dorzagliatin |
Search PubMed titles | dorzagliatin |
Search PubMed titles/abstracts | dorzagliatin |
UniChem Compound Search for chemical match using the InChIKey | HMUMWSORCUWQJO-QAPCUYQASA-N |
UniChem Connectivity Search for chemical match using the InChIKey | HMUMWSORCUWQJO-QAPCUYQASA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖
Dorzagliatin (links to external site)
Cat. No. HY-109030 |